Tag Archives: Sanofi Pasteur

MedImmune and Sanofi Pasteur to jointly develop and commercialise respiratory syncytial virus monoclonal antibody

LONDON, 03-Mar-2017 — /EuropaWire/ — MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, today announced an agreement to develop and commercialise MEDI8897 jointly. MEDI8897 is a monoclonal antibody (mAb) for the … Read the full press release

Sanofi Pasteur and MSD to separately pursue their own vaccine strategies in Europe

PARIS, 03-Jan-2017 — /EuropaWire/ — Sanofi and its vaccines global business unit Sanofi Pasteur confirmed today the end of their vaccine joint-venture with MSD (known as Merck & Co. Inc., in the United States and Canada), Sanofi Pasteur MSD (SPMSD). … Read the full press release

Dengue vaccine: Sanofi Pasteur’s Dengvaxia® receives regulatory approval in Brazil

Global introduction of the first Dengue Vaccine gains further momentum with this third approval in a row in an endemic country – With 1.4 million dengue cases reported this year, Brazil stands to gain tremendous value from this new dengue … Read the full press release

New England Journal of Medicine analyses: Sanofi Pasteur’s Vaccine Candidate Safely Protects Pre-Adolescents to Adults Against Dengue

– The highest burden of dengue disease globally in endemic countries is in pre-adolescent to adults age group[1],[2],[3] – In a new pooled analysis, dengue vaccine candidate protected two out of three volunteers aged 9 years and older against all four … Read the full press release

Sanofi Pasteur starts phase III clinical trial in India for its investigational rotavirus vaccine manufactured by its affiliate Shantha Biotechnics in Hyderabad, India

The live, oral, ready-to-use tetravalent rotavirus vaccine candidate is designed to protect young children from severe diarrhea Lyon, France, 15-10-2014 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi, announced today the start of a phase III clinical trial in India … Read the full press release

Sanofi Pasteur: The New England Journal of Medicine published positive results for Fluzone® High-Dose Vaccine

Study Demonstrates Fluzone High-Dose Vaccine 24.2 Percent More Effective Than Standard-Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older LYON, France, 19-8-2014 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), … Read the full press release

Sanofi Pasteur announced its pediatric pentavalent vaccine Shan5™ received prequalification status from the World Health Organization

Shan5™ is the first vaccine jointly developed by the Indian company and its parent company Sanofi Pasteur  WHO’s decision allows for the purchase of Shan5™ by United Nations agencies Lyon, France, 7-5-2014 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: … Read the full press release

Sanofi vaccines division Sanofi Pasteur initiated Cdiffense Phase III Study of investigational vaccine for prevention of primary symptomatic Clostridium difficile infection (CDI)

Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide Lyon, France, 06-8-2013 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program … Read the full press release